Defence Therapeutics Financials
| DTCFF Stock | USD 0.79 0.08 9.20% |
With this module, you can analyze Defence financials for your investing period. You should be able to track the changes in Defence Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Defence |
Understanding current and past Defence Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Defence Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Defence Therapeutics' assets may result in an increase in income on the income statement.
The data published in Defence Therapeutics' official financial statements typically reflect Defence Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Defence Therapeutics' quantitative information. For example, before you start analyzing numbers published by Defence accountants, it's essential to understand Defence Therapeutics' liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Defence Therapeutics Stock Summary
Defence Therapeutics competes with Sino Biopharmaceutica, Enlivex Therapeutics, Lixte Biotechnology, Benitec Biopharma, and Cingulate. Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar therapeutic drugs for cancer and infectious diseases. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada. Defence Therapeutics is traded on OTC Exchange in the United States.| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| Business Address | 1680 200 Burrard |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | defencetherapeutics.com |
| Phone | 514 947 2272 |
| Currency | USD - US Dollar |
Defence Therapeutics Key Financial Ratios
There are many critical financial ratios that Defence Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Defence Therapeutics reports annually and quarterly.| Return On Equity | -4.15 | |||
| Return On Asset | -1.79 | |||
| Z Score | -33.0 |
Defence Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Defence Therapeutics's current stock value. Our valuation model uses many indicators to compare Defence Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Defence Therapeutics competition to find correlations between indicators driving Defence Therapeutics's intrinsic value. More Info.Defence Therapeutics is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Defence Therapeutics' earnings, one of the primary drivers of an investment's value.Defence Therapeutics Systematic Risk
Defence Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Defence Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Defence Therapeutics correlated with the market. If Beta is less than 0 Defence Therapeutics generally moves in the opposite direction as compared to the market. If Defence Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Defence Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Defence Therapeutics is generally in the same direction as the market. If Beta > 1 Defence Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Defence Therapeutics March 2, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Defence Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Defence Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Defence Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Defence OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Defence Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 19.75 | |||
| Information Ratio | 0.1347 | |||
| Maximum Drawdown | 100.54 | |||
| Value At Risk | (15.22) | |||
| Potential Upside | 26.25 |
Complementary Tools for Defence OTC Stock analysis
When running Defence Therapeutics' price analysis, check to measure Defence Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Defence Therapeutics is operating at the current time. Most of Defence Therapeutics' value examination focuses on studying past and present price action to predict the probability of Defence Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Defence Therapeutics' price. Additionally, you may evaluate how the addition of Defence Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |